Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Innervace | 2022 | Series A | $40.0M | Philadelphia |
| ARS Pharmaceuticals | 2025 | Post-IPO Debt | $100.0M | San Diego |
| Pairwise Plants | 2024 | Series C | $40.0M | Durham |
| Spectrawave | 2024 | Series B | $50.0M | Waltham |
| Dracen Pharmaceuticals | 2023 | Debt Financing | $2.3M | Baltimore |
| Vesta Healthcare | 2024 | Debt Financing | $10.0M | New York |
| Vicinitas Therapeutics | 2022 | Series A | $65.0M | San Francisco |
| Strata Oncology | 2021 | Series C | $90.0M | Ann Arbor |
| Humanity Health | 2022 | Series A | $6.0M | New York |
| Adaptive Phage Therapeutics | 2023 | Series B | $12.0M | Bethesda |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Innervace | Series A | $40.0M | Philadelphia, United States |
| 2 | ARS Pharmaceuticals | Post-IPO Debt | $100.0M | San Diego, United States |
| 3 | Pairwise Plants | Series C | $40.0M | Durham, United States |
| 4 | Spectrawave | Series B | $50.0M | Waltham, United States |
| 5 | Dracen Pharmaceuticals | Debt Financing | $2.3M | Baltimore, United States |
| 6 | Vesta Healthcare | Debt Financing | $10.0M | New York, United States |
| 7 | Vicinitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 8 | Strata Oncology | Series C | $90.0M | Ann Arbor, United States |
| 9 | Humanity Health | Series A | $6.0M | New York, United States |
| 10 | Adaptive Phage Therapeutics | Series B | $12.0M | Bethesda, United States |
Innvervace develops regenerative therapy solutions for neurodegenerative disorders.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
Pairwise is a purpose-driven food+tech company dedicated to building a healthier world through better fruits and vegetables.
Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices.
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Vesta Healthcare is a technology and clinical services organization that offers virtual care services.
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives.
Strata Oncology is a precision oncology company dedicated to transforming cancer care.
Humanity Health is a platform for underrepresented leaders in healthcare and life sciences to accelerate and find talent.
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.
We provide simple, sophisticated respiratory solutions for post-ICU and home environments, eliminating unnecessary cost and complexity.
Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Twill is a technology healing firm that provides engaged communities, healthcare providers, mental health services, and treatment options.
Elutia is a developer of customized tissue products intended to restore health and mobility to the greatest number of patients.
R3 Vascular is a medical device company that develops new therapies to treat peripheral artery disease.
Abivax develops medicines that alter the body's natural immune system mechanisms.
Advantia Health provides medical services focused on women's healthcare and reproductive wellness.
Platform therapeutics company advancing novel treatments for Oncology, Neurodegenerative Disorders, and Rare Diseases
NeuroFlow is a HIPAA compliant digital health platform that optimizes the way behavioral healthcare is delivered, tracked, and assessed.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia.
Deerfield has invested in 160 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Deerfield's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 30 different industry categories.
Among tracked funding rounds, Bitterroot Bio received $145.0M in a Series A round. Deerfield's total known invested capital is $8.0B.
Deerfield's average investment size is $78.0M across its portfolio of 160 companies.
Recent Deerfield portfolio additions include Innervace, ARS Pharmaceuticals, Pairwise Plants, Spectrawave, Dracen Pharmaceuticals. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors